Merck and three partners start ExploreBio, a € 20 million pre-seed investment initiative in Israel

MerckMerck, a leading science and technology company, today announced ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel. For this purpose the strategic corporate venture capital arm of Merck has partnered with Arkin Holdings, Pontifax and WuXi AppTec to create the € 20 million pre-seed investment vehicle.

"Israel's start-up spirit is unique and so inspiring. We are proud to be an active part of this great success story. Now we are taking a next important investment step as we believe in the innovative potential of ExploreBio," said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.

ExploreBio is an initiative comprising pre-seed investments and management services for proof-of-concept-experiments in biotechnology. Additionally, companies benefiting from the ExploreBio initiative will be given the opportunity to work at Merck’s BioIncubator facilities in Yavne, Israel. Interested parties should submit their investment proposal here.

The commitment involves a total volume of € 20 million for five years. ExploreBio aims to invest € 1 million to € 1.5 million per company across up to four investments per year over a period of five years. The early-stage companies would benefit from quick access to funding and easy access to follow-up capital.

The four investors have worked together on investments in different companies in the past, such as Metabomed (targeted cancer therapy) and Artsavit (using apoptosis-induction to treat cancer).

With the new ExploreBio initiative, Merck and its three partners aim to engage with start-up companies in which it would otherwise be too early to invest. A second advantage for the four partners is being able to leverage the consortium’s resources and their strong relationships to work with the investments more closely and effectively.

ExploreBio complements Merck’s activities in helping early-stage companies in Israel to mature. Merck set up PMatX last year and has been running its BioIncubator in Yavne since 2011.

PMatX addresses the topic of next-generation electronics and is a joint endeavor with Flex, San Jose, California, USA, and also backed by additional industry partners including HP, Palo Alto, California, USA, and the U.S.- based global investment firm Battery Ventures. PMAtX is supported by the Technology Innovation Lab program of the Israel Innovation Authority (IIA). The overall investment volume of the program involving all parties is around € 20 million and the initial commitment is for three years.

Merck's site in Yavne houses the company’s Healthcare and Life Science incubator called BioIncubator. This successful undertaking was started in 2011 and has committed to invest up to € 10 million until 2018 in biomedically focused start-up companies in Israel.

Merck employs more than 300 people in Israel, mainly scientists, and has sites in Yavne, Herziliya, Rehovot, and Jerusalem. All three of its business sectors, Healthcare, Life Science and Performance Materials, have R&D sites in Israel.

Merck also announces today that the Israel Patent Office as well as the Korean Intellectual Property Office have each issued notices granting Merck's patent applications for the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells. These decisions mark the fifth and sixth patent allowances for Merck's unique CRISPR technology following Singapore, Australia, the European Union, and Canada. Merck also has patent filings for its insertion CRISPR method in the United States, Brazil, China, India, and Japan.

Arkin Holdings

Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies. Our synergistic healthcare investments are dedicated to creating innovations that benefit humanity and enhance medical care.

We offer extensive experience, with a track record of successful healthcare investments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth.

About Pontifax

Pontifax is a venture capital firm focusing on groundbreaking innovations in life sciences. We seek transformative healthcare technologies in all development stages.

Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with over $350 million under management. We seek transformative, cutting-edge life sciences technologies at all development stages. Our portfolio comprises of about 50 companies that develop breakthrough solutions to substantial unmet needs.

About WuXi AppTec

Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.

Strategic Corporate Venture Capital arm of Merck

MVentures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck’s core business areas. From our headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. We take an active role in its portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success. The venture capital arm of Merck has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck's science and technology base.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...